Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | January 09, 2023 | January 13, 2023 |
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Director | June 10, 2026 | June 12, 2026 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Executive Vice President, R&D | February 12, 2018 | February 14, 2018 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Medical Officer | February 11, 2021 | February 16, 2021 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date January 09, 2023 · Filed January 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-01-09 | Direct | 223,560 |
Reported balance
After 2023-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-09 · Grant · Acquired 223,560 · Balance 223,560 F1: On January 9, 2023, the Reporting Person was granted an option to purchase 223,560 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the one-year anniversary of the grant date of January 9, 2023. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 182,433 |
Reported balance
After 2023-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-09 · Grant · Acquired 182,433 · Balance 182,433 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On January 9, 2023, the Reporting Person was granted 182,433 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the anniversary of the grant date of January 9, 2023. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 9, 2023, the Reporting Person was granted an option to purchase 223,560 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the one-year anniversary of the grant date of January 9, 2023.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.
F4: On January 9, 2023, the Reporting Person was granted 182,433 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the anniversary of the grant date of January 9, 2023.
F5: Not applicable.
Camp4 Therapeutics Corp
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2036-06-09 | Direct | 28,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date.
NOVELION THERAPEUTICS INC.
Report date February 12, 2018 · Filed February 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2028-02-12 | Direct | 45,000 |
Reported balance
After 2018-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-12 · Grant · Acquired 45,000 · Balance 45,000 F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2: The option shall vest and become exercisable in three equal annual installments on February 12, 2019, February 12, 2020, and February 12, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
F2: The option shall vest and become exercisable in three equal annual installments on February 12, 2019, February 12, 2020, and February 12, 2021.
RHYTHM PHARMACEUTICALS, INC.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,375 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 9,375 · Balance 9,375 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.66 · Expires 2031-02-10 | Direct | 56,250 |
Reported balance
After 2021-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-11 · Grant · Acquired 56,250 · Balance 56,250 F3: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date
F3: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
X4 Pharmaceuticals, Inc
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2036-01-01 | Direct | 0 |
Reported balance
After 2026-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 110,000 · Balance 0 F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 16:15 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001628280-26-042859 · wk-form4_1781295346.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:04 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001501697-26-000005 · wk-form4_1767647080.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030504 · wk-form4_1749587446.xml · nonDerivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,883 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 16:07 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 17,787 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001736730-25-000011 · wk-form4_1742414847.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,787 Underlying: Common Stock · 17,787 shares Expires 2035-03-16 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of three years commencing from the date of grant. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027675 · wk-form4_1718136772.xml · nonDerivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,504 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 23:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 130,056 | $1.06 | $137,859.36 |
DisclosureSEC source: 0001628280-23-029148 · wk-form4_1691796370.xml · nonDerivative · entry 2 Stewart Murray · CIK 0001723450 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,504 F2 · kind: Represents nondiscretionary sale of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 23:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 269,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029148 · wk-form4_1691796370.xml · nonDerivative · entry 1 Stewart Murray · CIK 0001723450 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,560 F1 · shares: Represents shares of common stock acquired upon acceleration of the vesting of a performance-based restricted stock unit grant. Read SEC document |
| January 09, 2023 Filed Jan 13, 2023 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 182,433 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000403 · primarydocument.xml · derivative · entry 2 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,433 Underlying: Ordinary Shares · 182,433 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On January 9, 2023, the Reporting Person was granted 182,433 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the anniversary of the grant date of January 9, 2023. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 09, 2023 Filed Jan 13, 2023 01:03 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 223,560 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001562180-23-000403 · primarydocument.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,560 Underlying: Ordinary Shares · 223,560 shares Expires 2033-01-09 F1 · derivative.exercise_date: On January 9, 2023, the Reporting Person was granted an option to purchase 223,560 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the one-year anniversary of the grant date of January 9, 2023. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 06, 2022 Filed Jun 27, 2022 20:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018050 · wf-form4_165636093576773.xml · nonDerivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. F2 · balance_after: Represents unvested RSUs. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 21:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,000 | $9.50 Strike: $9.50 | $57,000.00 |
DisclosureSEC source: 0001628280-21-011544 · wf-form4_162266776504487.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:27 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 56,250 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-21-024413 · tm216849-3_4seq1.xml · derivative · entry 2 Stewart Murray · CIK 0001723450 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2031-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:27 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024413 · tm216849-3_4seq1.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date Read SEC document |
| October 20, 2020 Filed Oct 21, 2020 20:58 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001628280-20-014661 · wf-form4_160331389771325.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-10-19 F1 · derivative.exercise_date: 33.3333% of the shares subject to the option shall vest on October 20, 2021, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the grant, subject to the Reporting Person's continued services as a director through each applicable vesting date. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:06 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080538 · a4.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 12:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 3,427 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001628280-20-009234 · wf-form4_159187834596343.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2030-06-09 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:23 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 88,000 | $0.00 Strike: $17.87 | $0.00 |
DisclosureSEC source: 0001104659-20-022827 · a4.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2020 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 14, 2020. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 23:57 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,854 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0000899243-19-009663 · doc4.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2029-03-29 F1 · derivative.exercise_date: 33.3333% of the shares subject to the option shall vest on March 29, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject the Reporting Person continuing to provide services through each such date. This option was granted automatically upon the Reporting Person's election to the Board of Directors of the Issuer. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009041 · a4.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $26.54 | $0.00 |
DisclosureSEC source: 0001104659-18-062553 · a4.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-10-14 F1 · derivative.exercise_date: The option vests as follows: (1) 25% on October 15, 2019, and (2) the remaining 75% in 12 equal quarterly installments. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 07:01 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001104659-18-009353 · a4.xml · derivative · entry 1 Stewart Murray · CIK 0001723450 · Executive Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The option shall vest and become exercisable in three equal annual installments on February 12, 2019, February 12, 2020, and February 12, 2021. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 16:04 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001104659-17-070961 · a4.xml · derivative · entry 2 Stewart Murray · CIK 0001723450 · Executive Vice President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2027-11-27 F3 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F4 · derivative.exercise_date: This stock option award will vest and become exercisable in three equal annual installments beginning November 27, 2018. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 16:04 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-070961 · a4.xml · nonDerivative · entry 1 Stewart Murray · CIK 0001723450 · Executive Vice President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: These shares are issuable pursuant to a grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The restricted stock units vest in three equal annual installments beginning November 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.